Tbio SMARCB1 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1

Protein Summary

Description

Core component of the BAF (hSWI/SNF) complex. This ATP-dependent chromatin-remodeling complex plays important roles in cell proliferation and differentiation, in cellular antiviral activities and inhibition of tumor formation. The BAF complex is able to create a stable, altered form of chromatin that constrains fewer negative supercoils than normal. This change in supercoiling would be due to the conversion of up to one-half of the nucleosomes on polynucleosomal arrays into asymmetric structures, termed altosomes, each composed of 2 histones octamers. Stimulates in vitro the remodeling activity of SMARCA4/BRG1/BAF190A. Involved in activation of CSF1 promoter. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a postmitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to postmitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth (By similarity). Plays a key role in cell-cycle control and causes cell cycle arrest in G0/G1. The protein encoded by this gene is part of a complex that relieves repressive chromatin structures, allowing the transcriptional machinery to access its targets more effectively. The encoded nuclear protein may also bind to and enhance the DNA joining activity of HIV-1 integrase. This gene has been found to be a tumor suppressor, and mutations in it have been associated with malignant rhabdoid tumors. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Dec 2015]

Uniprot Accession IDs

• Q12824
• O75784
• O95474
• Q17S11
• Q38GA1
• Q76N08
• Q9UBH2

Gene Name

• SMARCB1

Ensembl ID

• ENST00000407422
• ENSP00000383984
• ENSG00000099956
• ENST00000618915
• ENSP00000479330
• ENSG00000275837
• ENST00000631333
• ENSP00000486870
• ENST00000644036
• ENSP00000494049

Symbol

• BAF47
• INI1
• SNF5L1
• RDT
• CSS3
• INI1
• SNF5
• Snr1
• BAF47
• MRD15
• RTPS1
• Sfh1p
• hSNFS
• SNF5L1
• SWNTS1
• PPP1R144

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
hub protein	1
virus	0.98
disease perturbation	0.97
protein complex	0.97
molecular function	0.96

Protein Classes

PANTHER Classes

Protein / Nucleic Acid Binding / Dna Binding Protein / Swi/snf-related Matrix-associated Actin-dependent Regulator Of Chromatin Subfamily B Member 1

DTO Classes

Protein / Nucleic Acid Binding / Dna Binding Protein / Swi/snf-related Matrix-associated Actin-dependent Regulator Of Chromatin Subfamily B Member 1

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 1173.87   (req: < 5)

Gene RIFs: 287   (req: <= 3)

Antibodies: 471   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 1173.87   (req: >= 5)

Gene RIFs: 287   (req: > 3)

Antibodies: 471   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 24

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0